According to GuruFocus Insider Data, the recent CFO buys were: BioDelivery Sciences International Inc. (BDSI, Financial), TheStreet Inc. (TST, Financial) and Antares Pharma Inc. (ATRS, Financial).
BioDelivery Sciences International Inc. (BDSI, Financial): CFO, Secretary and Treasurer Ernest Robert De Paolantonio bought 4,000 shares
On March 17, Paolantonio bought 4,000 shares at an average price of $2.6. The price of the stock has increased by 14.23%. Biodelivery Sciences International Inc. has a market cap of $158.8 million and its shares were traded around $2.97. The company has a P/S ratio of 3.23.
BioDelivery Sciences International Inc. announced its 2015 fourth quarter results with revenues of $32.21 million and gross profit of $29.55 million, while the net income was $10.17 million. The 2015 total revenue was $48.23 million, a 24% increase from the 2014 total revenue. The 2015 gross profit was $40.13 million, an 18% increase from the 2014 gross profit. The 2015 net loss was $37.67 million.
On March 21, Director Charles Bramlage bought 8,850 shares at an average price of $2.82. The price of the stock has increased by 5.32%. On March 18, Chief Technology Officer Niraj Vasisht bought 1,000 shares at an average price of $2.8. The price of the stock has increased by 6.07%. On March 18, Director Barry Feinberg bought 10,000 shares at an average price of $2.74. The price of the stock has increased by 8.39%.
TheStreet Inc. (TST, Financial): CFO Eric F Lundberg bought 6,598 shares
On Mar. 21, Lundberg bought 6,598 shares at an average price of $1.2. The price of the stock has increased by 2.5%. TheStreet Inc. has a market cap of $43.33 million and its shares were traded around $1.23. The company has a P/S ratio of 0.63. The trailing 12-month dividend yield of the stock is 8.13%, while the forward dividend yield is 8.13%.
TheStreet announced its 2015 fourth quarter results with revenues of $16.97 million and gross profit of $8.97 million, while the net loss was $249,000. The 2015 total revenue was $67.66 million, an 11% increase from the 2014 total revenue. The 2015 gross profit was $34.04 million, a 16% increase from the 2014 gross profit. The 2015 net loss was $1.54 million.
On Nov. 11, CEO Elisabeth H Demarse bought 40,000 shares at an average price of $1.63. The price of the stock has decreased by 24.54%. On March 23, Director Lawrence S Kramer bought 42,013 shares at an average price of $1.19. The price of the stock has increased by 3.36%. On March 14, Director Stephen Zacharias bought 40,000 shares at an average price of $1.12. The price of the stock has increased by 9.82%.
Antares Pharma Inc. (ATRS, Financial): Senior Vice President and CFO James E Fickenscher bought 135,000 shares
On March 18, Fickenscher bought 135,000 shares at an average price of $0.72. Antares Pharma Inc. has a market cap of $110.380 million and its shares were traded around 71 cents. The company has a P/S ratio of 2.29. Over the past five years, Antares Pharma Inc. had an annual average earnings growth of 28.70%.
Antares Pharma announced its 2015 fourth quarter results with revenues of $11.80 million and gross profit of $5.83 million, while the net loss was $6.63 million. The 2015 total revenue was $45.66 million, a 72% increase from the 2014 total revenue. The 2015 gross profit was $26.2 million, a 72% increase from the 2014 gross profit. The 2015 net loss was $20.66 million.
On March 18, President and CEO Robert F Apple bought 60,000 shares at an average price of 72 cents. On March 21, SVP General Counsel and Secretary Peter J Graham bought 20,000 shares at the average price of 77 cents. On March 18, Director Anton Gueth bought 50,000 shares of ATRS stock at the average price of 72 cents.
